Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Breast Neoplasms 5Glioma 4Glioblastoma 4Neoplasms 3Gliosarcoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Relapsed Pediatric Solid Tumor 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precancerous Conditions 1Pleural Effusion 1Pheochromocytoma 1

Interventions

pazopanib 2Ifosfamide 2Etoposide 2Carboplatin 2vandetanib 1ruxolitinib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Relapsed Pediatric Solid Tumor × vandetanib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡